
Pharma Business - December 17, 2015
AstraZeneca makes strategic investment in China
AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced a range of strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China, the company’s second largest market globally and a key growth platform. The initiatives and investments include: * A strategic alliance with WuXi AppTec, a […]

New Market - June 15, 2013
To the East
The Chinese market is without doubt one that is highly sought-after by many companies seeking to expand their business. Before you enter this land of opportunities, here are some dos and don’ts to ponder. Since initiating market reforms in 1978, China has shifted from a centrally planned to a market based economy and has experienced […]